World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
95
Citations
32841
World Ranking
899
National Ranking
500

Medicine

D-Index
95
Citations
32808
World Ranking
10075
National Ranking
5188

Dimiter S. Dimitrov publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Dimiter S. Dimitrov sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 388 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Dimiter S. Dimitrov D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Dimiter S. Dimitrov sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 95 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Dimiter S. Dimitrov is affiliated with the University of Pittsburgh in the United States. Their research spans multiple areas within medicine and biochemistry, genetics, and molecular biology, with a notable focus on oncology, infectious diseases, and immunology.

The scientist's prominent research topics include:

  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • SARS-CoV-2 and COVID-19 Research
  • Neuroblastoma Research and Treatments
  • Immune Cell Function and Interaction
  • Virus-based gene therapy research
  • Immunotherapy and Immune Responses

Dimiter S. Dimitrov's recent papers demonstrate a diverse involvement in cutting-edge biomedical research. Key publications include:

  • "Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies," 2021, PLoS Biology
  • "Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies," 2020, Cancer Cell
  • "GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity," 2021, Cancer Cell
  • "Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models," 2021, Science Translational Medicine
  • "Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study," 2020, The Lancet Infectious Diseases

Frequent co-authors who have collaborated extensively with Dimiter S. Dimitrov include:

  • Wei Li (38 publications)
  • John W. Mellors (28 publications)
  • Zehua Sun (23 publications)
  • Poul H. Sorensen (17 publications)
  • Rimas J. Orentas (15 publications)

Dimitrov's work has been published repeatedly in a range of scientific venues. The most common publication venues include:

  • Cancer Research (17 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (9 publications)
  • Nature Communications (6 publications)
  • UNC Libraries (4 publications)
  • Regular and Young Investigator Award Abstracts (4 publications)

The main fields of study for Dimitrov's research articles are medicine with 197 publications and biochemistry, genetics, and molecular biology with 61 publications. Subfields with significant volume of research output include oncology, radiology and nuclear medicine, molecular biology, infectious diseases, and immunology.

Best Publications

  • CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

    Terry J Fry;Nirali N Shah;Rimas J Orentas;Maryalice Stetler-Stevenson

  • Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Leonid Cherkassky;Aurore Morello;Jonathan Villena-Vargas;Yang Feng

  • HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

    Richard T. Davey;Niranjan Bhat;Christian Yoder;Tae Wook Chun

  • Structural definition of a conserved neutralization epitope on HIV-1 gp120.

    Tongqing Zhou;Ling Xu;Barna Dey;Ann J. Hessell

  • Structure of a V3-Containing HIV-1 gp120 Core

    Chih-chin Huang;Min Tang;Mei-Yun Zhang;Shahzad Majeed

  • Evaluation of gene expression measurements from commercial microarray platforms

    Paul K. Tan;Thomas J. Downey;Edward L. Spitznagel;Pin Xu

  • Virus entry: molecular mechanisms and biomedical applications

    Dimiter S. Dimitrov

  • Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

    Waleed Haso;Daniel W. Lee;Nirali N. Shah;Maryalice Stetler-Stevenson

  • CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

    Robbie G. Majzner;Johanna L. Theruvath;Anandani Nellan;Sabine Heitzeneder

  • Quantitation of human immunodeficiency virus type 1 infection kinetics.

    D. S. Dimitrov;R. L. Willey;H. Sato;Lung-Ji Chang

  • Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

    Masashi Shingai;Yoshiaki Nishimura;Florian Klein;Hugo Mouquet

  • Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus

    Matthew I. Bonaparte;Antony S. Dimitrov;Katharine N. Bossart;Gary Crameri

  • The SARS-CoV S glycoprotein: expression and functional characterization.

    Xiaodong Xiao;Samitabh Chakraborti;Anthony S Dimitrov;Kosi Gramatikoff

  • Evidence for Cell-Surface Association Between Fusin and the CD4-gp120 Complex in Human Cell Lines

    Cheryl K. Lapham;Jun Ouyang;Bhaskar Chandrasekhar;Nga Y. Nguyen

  • Distinctions Between CD8+ and CD4+ T-Cell Regenerative Pathways Result in Prolonged T-Cell Subset Imbalance After Intensive Chemotherapy

    Crystal L. Mackall;Thomas A. Fleisher;Thomas A. Fleisher;Margaret R. Brown;Margaret R. Brown;Mary P. Andrich;Mary P. Andrich

  • Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

    Aran F. Labrijn;Pascal Poignard;Aarti Raja;Michael B. Zwick

  • Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

    Steven Seaman;Zhongyu Zhu;Saurabh Saha;Xiaoyan M. Zhang

  • Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

    Lei Chen;Young Do Kwon;Tongqing Zhou;Xueling Wu

  • Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

    Xiaodong Xiao;Weizao Chen;Yang Feng;Zhongyu Zhu

  • A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.

    Katharine N. Bossart;Zhongyu Zhu;Deborah Middleton;Jessica Klippel

  • Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

    Chih-chin Huang;Miro Venturi;Shahzad Majeed;Michael J. Moore

  • Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles

    Hironori Sato;Jan Orensteint;Dimiter Dimitrov;Malcolm Martin

Frequent Co-Authors

Christopher C. Broder
Christopher C. Broder Uniformed Services University of the Health Sciences
Tianlei Ying
Tianlei Ying Fudan University
Dennis R. Burton
Dennis R. Burton Scripps Research Institute
Richard T. Wyatt
Richard T. Wyatt Scripps Research Institute
Peter D. Kwong
Peter D. Kwong Columbia University Medical Center
Shibo Jiang
Shibo Jiang Fudan University
Robert Blumenthal
Robert Blumenthal University of Toledo
Joseph Sodroski
Joseph Sodroski Harvard Medical School
Tongqing Zhou
Tongqing Zhou National Institutes of Health
Michael B. Zwick
Michael B. Zwick Scripps Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their career in Immunology, particularly within healthcare, exploring specialized nursing pathways can be a strategic move. Many professionals transition from general nursing roles to more focused areas, such as becoming an Acute Care Nurse Practitioner (NP). Earning an acute care NP certification equips nurses to manage complex health conditions, which is valuable when dealing with immunological disorders.

For accelerated career advancement, enrolling in accelerated NP programs offers a flexible way to obtain a nurse practitioner degree online. These programs often accommodate working professionals and help speed up the educational process.

Individuals without a nursing background can also enter the field through 12-month accelerated nursing programs online for non nurses, designed to fast-track foundational nursing education. After completing these, there are further options for specialization and certification.

Similarly, accelerated BSN programs for non nurses provide a solid nursing foundation and are particularly popular among career changers aiming to enter health sciences, including Immunology-related pathways.

Best Scientists Citing Dimiter S. Dimitrov

Trending Scientists